Skip to main content

Dianthus Therapeutics, Inc.

DNTH
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001690585

In the last 90 days, Dianthus Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 269 institutions reported holding it in 13F filings for Q2 2026, worth $6.40B in total; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Dianthus Therapeutics, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of DNTH: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders7254−18
Shares46.6M28.1M−18.5M (−39.6%)
Value$65.8M$11.1M−$54.6M (−83.1%)

New holders (7)

Institutions that held Dianthus Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to DNTH in Q4 2022
InstitutionSharesValue% of portfolio
Leonteq Securities AG180,000$71.1K0.00%
Thrivent Financial for Lutherans129,395$47.0K0.00%
Engineers Gate Manager LP34,090$13.5K0.00%
National Asset Management, Inc.28,000$11.1K0.00%
StoneX Group Inc.12,237$4.83K0.00%
Belpointe Asset Management LLC5,500$2.17K0.00%
Pension & Wealth Management Advisors, Inc.10$40.00%

Sold out (25)

Institutions that held Dianthus Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.